What do you do on a windy, cloudy, raining Sunday in NJ?
Follow tweets from the ASCO of course.
My Twitter news stream was filled with comments on these two non-gyn cancer studies.
Breast Cancer -
The Adjuvant Chemo and 21 Gene Expression Assay study reported at ASCO by Dr J Sparano may be found in this NJEM article https://www.nejm.org/doi/10.1056/NEJMoa1804710
"Investigators “found that gene tests on tumor samples were able to identify women who could safely skip
chemotherapy and take only a drug that blocks the hormone estrogen or stops the body from making it.”
From the ASCO Cancer in the News e-mail .
Lung Cancer - Keytruda Study (Pembroluzimab)
Keytruda "boosts the immune system outperforms chemotherapy in fighting advanced lung cancer, a new trial shows. Keytruda
(pembrolizumab) extended life four to eight months longer than
chemotherapy in lung cancer patients whose immune systems had been duped
by their cancer cells.
"This trial shows that pembrolizumab used
alone improves survival as opposed to chemotherapy," said lead
researcher Dr. Gilberto Lopes, a medical oncologist with the Sylvester
Comprehensive Cancer Center at the University of Miami Health System."
From HealthDay / ASCO Cancer in the News e-mail.
Now on to the gyn Tweets/ Studies.
OVARIAN CANCER :
Keynote - niraparib and pembrolizumab
(Median duration response rate of 9.3 months)
HPV / Cervical Cancer
Will check into the #gyncsm and #ASCO18 tweet streams a few times today to catch more news from the meeting. If you are there feel free to use those hashtags or tag me @womenofteal in your posts.
Every Day is a Blessing!